Standard Induction Followed by Low Dose Cytarabine for the Treatment of Acute Myeloid Leukemia of Down Syndrome
- Author:
Ye Chan KYUNG
1
;
Young Bae CHOI
;
Na Hee LEE
;
Soo Hyun LEE
;
Ki Woong SUNG
;
Hong Hoe KOO
;
Keon Hee YOO
Author Information
1. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. hema2170@skku.edu
- Publication Type:Multicenter Study
- Keywords:
Acute myeloid leukemia;
Down syndrome;
Low dose cytarabine;
Post-remission therapy
- MeSH:
Cytarabine;
Diagnosis;
Down Syndrome;
Drug Therapy;
Fever;
Follow-Up Studies;
Humans;
Leukemia, Myeloid, Acute;
Medical Records
- From:Clinical Pediatric Hematology-Oncology
2014;21(2):80-85
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Although acute myeloid leukemia occurring in patients with Down syndrome (AML-DS) is generally chemosensitive, these patients are more susceptible to regimen-related toxicities, and the optimal post-remission therapy for AML-DS is unknown. This study aimed to evaluate the outcome of post-remission chemotherapy using low dose cytarabine for AML-DS.METHODS: We reviewed the medical records of 142 patients who were newly diagnosed as de novo AML between 1996 and 2011. Among them, 8 patients (5.6%) had Down syndrome. Seven patients received standard induction therapy composed of cytarabine (or behenoyl cytarabine) and anthracycline. Once complete remission (CR) was achieved, repetitive courses of low dose cytarabine were given.RESULTS: Patients' median age at diagnosis was 1.3 years (range, 0.4-1.9). All but one showed French-American-British (FAB) M7 morphology. Six patients achieved CR (75%) after induction therapy and then received 9 to 20 courses (median, 14) of low dose cytarabine. One patient had 2 episodes of neutropenic fever, whereas the other 5 patients did not suffer from any complication. All six patients are alive event-free with a median follow-up of 118 months (range, 33-208). The estimated 5-year overall survival of all 8 AML-DS patients was 87.5%, while that of non-DS de novo AML patients was 58.6% (P=0.18).CONCLUSION: Low dose cytarabine was safe and effective as a post-remission therapy for AML-DS. Due to the rarity of AML-DS, a multicenter cooperative study is essential to identify the optimal duration of treatment and to further determine the feasibility of low dose cytarabine for these patients.
